Found 27 matching trials
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
PHASE3Infection with human papillomavirus (HPV) has been clearly established as t...
Location
GSK Investigational Site
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
PHASE3This protocol posting deals with objectives \& outcome measures of the exte...
Location
GSK Investigational Site
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
PHASE3This extension study is conducted to assess the efficacy of the GSK 580299 ...
Location
GSK Investigational Site
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
PHASE2Infection with human papillomavirus (HPV) has been clearly established as t...
Location
GSK Investigational Site
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
PHASE3Infection with human papillomavirus (HPV) has been clearly established as t...
Location
GSK Investigational Site
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
PHASE3This study has been designed to evaluate the immunogenicity and safety of G...
Location
GSK Investigational Site
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
PHASE3This study is designed to evaluate the immunogenicity and safety of GlaxoSm...
Location
GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
PHASE4Infection with human papillomavirus (HPV) has been clearly established as t...
Location
GSK Investigational Site
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
PHASE2The goals of this study are to describe the safety, reactogenicity and immu...
Location
Multiple Locations
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
PHASE3Infection with human papillomavirus (HPV) has been clearly established as t...
Location
GSK Investigational Site